REDWOOD CITY, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present at the following upcoming investor conferences: 2024 RBC Global Healthcare Conference on Tuesday, May 14, 2024 at 4:05 p.m.

加利福尼亚州红木市，2024年5月3日（环球通讯社）--Adverum Biotechnologies，Inc.（纳斯达克：ADVM），一家临床阶段公司，率先将基因治疗作为高度流行的眼部疾病的新护理标准，今天宣布该公司将出席以下即将举行的投资者会议：2024年5月14日星期二下午4:05举行的2024 RBC全球医疗保健会议。

ET.BofA Securities 2024 Health Care Conference on Wednesday, May 16, 2024 at 3:40 p.m. PT.H.C. Wainwright 2nd Annual BioConnect Investor Conference on Monday, May 20, 2024 at 11:00 a.m. ET. The on-demand webcast of the panel discussion may be accessed under Events and Presentations in the Investors section of Adverum’s website.

ET.BofA Securities 2024 Health Care Conference于2024年5月16日星期三下午3:40 PT.H.C.Wainwright于2024年5月20日星期一上午11:00举行第二届BioConnect投资者年会。小组讨论的点播网络广播可在Adverum网站投资者部分的活动和演示下访问。

A replay of the webcast will be available on the website for at least 30 days following the presentation. About Adverum Biotechnologies Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness.

演示后至少30天内，网站将提供网络广播的重播。关于Adverum Biotechnologies Adverum Biotechnologies（纳斯达克：ADVM）是一家临床阶段公司，旨在建立基因治疗作为高度流行的眼部疾病的新护理标准，旨在开发功能性治疗以恢复视力和预防失明。

Leveraging the capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration.

Adverum利用其专有的玻璃体内（IVT）平台的功能，正在开发持久的单次给药疗法，旨在在医生办公室提供，以消除频繁眼部注射治疗这些疾病的需要。Adverum正在评估其新型基因治疗候选药物ixoberogene Soropavec（Ixo-vec，以前称为ADVM-022），作为新生血管或湿性年龄相关性黄斑变性患者的一次性IVT注射。

Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve visio.

此外，通过克服与目前使人衰弱的眼部疾病的治疗模式相关的挑战，Adverum渴望改变护理标准，保持visio。